The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

María-Victoria Mateos’s top 3 breakthroughs in transplant for myeloma

Sep 3, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to our Co-Chair María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked for her top 3 breakthroughs in transplant for myeloma.

María-Victoria Mateos’s top 3 breakthroughs in transplant for myeloma

María-Victoria Mateos first talks about the emergence of measurable residual disease (MRD) as a possible surrogate marker for clinical outcome, or even for cure, in newly diagnosed multiple myeloma. She goes on to discuss the importance of autologous stem cell transplantation (auto-SCT) and its success in treating newly diagnosed patients. But despite this, in 2020, there have been preliminary findings suggesting that auto-SCT could be delayed or skipped in certain patients. María-Victoria Mateos concludes by mentioning bispecific antibodies and CAR T cells. In the future, these may be used in earlier stages of myeloma treatment and come to challenge the use of auto-SCT.